NatWest Rises, Sanofi Climbs, Saab Surges
On this episode of Stock Movers:- NatWest raised its guidance for the year after beating estimates in the 3Q, delivering its highest earnings in at least a decade.- Sanofi’s profit rose more than analysts expected last quarter, lifted by demand for its blockbuster skin and asthma drug Dupixent. - Saab boosted its organic revenue forecast for the full year, benefiting from the uncertainty of the geopolitical landscape, adding it's received a record high order backlog.See omnystudio.com/listener for privacy information.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.